Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing

Kosuke Kato; Yoon-Joo Shin; Sunny Palumbo; Ioannis Papageorgiou; Seongmin Hahn; Joseph D Irish; Skye P Rounseville; Robert T Krafty; Lutz Wollin; Maor Sauler; Louise Hecker

doi:10.1183/13993003.00759-2021

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing

Eur Respir J. 2021 Nov 25;58(5):2100759. doi: 10.1183/13993003.00759-2021. Print 2021 Nov.

Authors

Affiliations

¹ Division of Pulmonary, Allergy and Critical Care and Sleep Medicine, Dept of Medicine, Emory University, Atlanta, GA, USA.
² Division of Pulmonary, Allergy and Critical Care and Sleep Medicine, Dept of Medicine, University of Arizona, Tucson, AZ, USA.
³ Dept of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
⁴ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
⁵ Dept of Medicine, Yale School of Medicine, New Haven, CT, USA.
⁶ Division of Pulmonary, Allergy and Critical Care and Sleep Medicine, Dept of Medicine, Emory University, Atlanta, GA, USA louise.hecker@emory.edu.
⁷ Atlanta VA Healthcare System, Atlanta, GA, USA.

Abstract

Although nintedanib is overwhelmingly prescribed to elderly patients, this is the first study to demonstrate that ageing does not impact the efficacy of nintedanib. This study sheds light on the utility of aged animal models in pulmonary fibrosis. https://bit.ly/3zA9RC5

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Aging
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Indoles* / therapeutic use
Protein Kinase Inhibitors

Substances

Indoles
Protein Kinase Inhibitors
nintedanib

Abstract

Publication types

MeSH terms

Substances

Grants and funding